Trial Outcomes & Findings for Web-based Addiction Treatment: Cultural Adaptation With American Indians (NCT NCT03363256)

NCT ID: NCT03363256

Last Updated: 2026-05-19

Results Overview

Each week was categorized as abstinent if the urine screen was negative and the self-report indicated no drug use and no heavy drinking days and not abstinent if either urine screen or self-report indicated drug use or heavy drinking. If the urine screen was missing, TLFB self-report data was used.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

53 participants

Primary outcome timeframe

12 weeks (following randomization)

Results posted on

2026-05-19

Participant Flow

Participant milestones

Participant milestones
Measure
TAU + TES-NAV (Digital Intervention)
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN
TAU (Standard Outpatient Addiction Treatment)
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
Overall Study
STARTED
27
26
Overall Study
COMPLETED
27
26
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Web-based Addiction Treatment: Cultural Adaptation With American Indians

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
TAU + TES-NAV (Digital Intervention)
n=27 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN.
TAU (Standard Outpatient Addiction Treatment)
n=26 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
Total
n=53 Participants
Total of all reporting groups
Age, Continuous
37.0 Years
STANDARD_DEVIATION 10.2 • n=30 Participants
40.2 Years
STANDARD_DEVIATION 10.3 • n=30 Participants
38.6 Years
STANDARD_DEVIATION 10.3 • n=60 Participants
Sex/Gender, Customized
Female
12 Participants
n=30 Participants
12 Participants
n=30 Participants
24 Participants
n=60 Participants
Sex/Gender, Customized
Male
14 Participants
n=30 Participants
14 Participants
n=30 Participants
28 Participants
n=60 Participants
Sex/Gender, Customized
Other
1 Participants
n=30 Participants
0 Participants
n=30 Participants
1 Participants
n=60 Participants
Race (NIH/OMB)
American Indian or Alaska Native
23 Participants
n=30 Participants
19 Participants
n=30 Participants
42 Participants
n=60 Participants
Race (NIH/OMB)
Asian
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=30 Participants
1 Participants
n=30 Participants
1 Participants
n=60 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Race (NIH/OMB)
White
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Race (NIH/OMB)
More than one race
4 Participants
n=30 Participants
6 Participants
n=30 Participants
10 Participants
n=60 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=30 Participants
4 Participants
n=30 Participants
6 Participants
n=60 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
n=30 Participants
22 Participants
n=30 Participants
47 Participants
n=60 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants

PRIMARY outcome

Timeframe: 12 weeks (following randomization)

Each week was categorized as abstinent if the urine screen was negative and the self-report indicated no drug use and no heavy drinking days and not abstinent if either urine screen or self-report indicated drug use or heavy drinking. If the urine screen was missing, TLFB self-report data was used.

Outcome measures

Outcome measures
Measure
TAU + TES-NAV (Digital Intervention)
n=27 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN.
TAU (Standard Outpatient Addiction Treatment)
n=26 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
Consecutive Weeks of Drug/Alcohol Abstinence
2.0 Weeks
Interval 1.0 to 11.0
2.0 Weeks
Interval 1.0 to 6.0

Adverse Events

TAU + TES-NAV (Digital Intervention)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

TAU (Standard Outpatient Addiction Treatment)

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
TAU + TES-NAV (Digital Intervention)
n=27 participants at risk
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN.
TAU (Standard Outpatient Addiction Treatment)
n=26 participants at risk
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
Injury, poisoning and procedural complications
Suicide attempt
0.00%
0/27 • From enrollment until the end of follow up (on average 24 weeks)
3.8%
1/26 • From enrollment until the end of follow up (on average 24 weeks)

Other adverse events

Adverse event data not reported

Additional Information

Aimee Campbell, PhD

New York State Psychiatric Institute

Phone: 646-774-6138

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place